Roundtable on Black in cancer research and oncology - presented by Dr. Brandon Blue MD and Dr. Kilan Ashad-Bishop and Drs. Onyinye and Folu Balogun and Runcie C.W. Chidebe Dip., BSc., MSc., and Kathryn Mcginnis and Dr Paraskevi Mallini and Dr. Lisa Hoffmann-Haas

Roundtable on Black in cancer research and oncology

Brandon Blue, Kilan Ashad-Bishop, Onyinye and Folu Balogun and Runcie C.W. Chidebe

Dr. Brandon Blue MDDr. Kilan Ashad-BishopDrs. Onyinye and Folu BalogunRuncie C.W. Chidebe Dip., BSc., MSc.,
Slide at 46:41
Call to Action Runcie Chidebe Figure 2 summarizes patients enrolled in the clinical trial by race. THE LANCET Figure 2. Baseline Demographics by Race Submit Article Oncology Access provided by Miami University ARTICLES I VOLUME 22,ISSUE 5,P609-619,MAY 2021 Download Full Issue White (96 patients) Efficacy and safety of tisotumab vedotin in previously treated recurrent or Black or African American (1 patient) metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Asian (2 patients) Robert L Coleman, MD Prof Domenica Lorusso MD Christine Gennigens, MD Prof Antonio Gonzalez-Martin, MD Leslie Randall, MD David Cibula, MD Show all authors Show footnotes Other (2 patients) Published: April 09, 2021 DOI: https://doi.org/10.1016/S1470-2045(21)00056-5 Check for If dates and safety of tisot cervical cancer(innovaTV arm.phase 2 study Source: Adapted from FDA Review Source: U.S. FDA www.projectpinkblue.org @projectpinkblue@runciecwo
1
2
3
References
  • 1.
    R. L. Coleman et al. (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology
  • 2.
    https://twitter.com/runciecwc
  • 3.
    https://twitter.com/projectpinkblue
Share slide
Summary (AI generated)

In low and middle-income countries, particularly in Africa, the burden of cervical cancer poses the greatest risk. However, there is hope in the form of medication that could potentially offer these women the chance to witness their grandchildren grow and truly experience life. It is disheartening to note that only one Black patient was included in the clinical trial conducted for this medication. The remaining participants consisted of 96 individuals who are all White, two Asians, and two whose racial background is unknown.